olig2- cre mice Search Results


90
Jackson Laboratory olig2-cre transgenic mice
Prrc2a modulates oligodendroglia fate determination, proliferation, and differentiation in vitro. a Immunostainings of Pdgfrα/Olig2 or <t>GFAP</t> in oligosphere-derived cells 14 days postBl04-CM treatment from mice with indicated genotypes. b Quantification of the percentage of Pdgfrα + Olig2 + and GFAP + cells from mice with indicated genotypes (one-way ANOVA followed Tukey test, ** P < 0.01, n = 4 each group). c Gene expressions during neurosphere to oligosphere transformation in cells 14 days post B104-CM treatment. The gene expressions were normalized to those in wild-type neural stem cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). d Immunostainings of Pdgfrα and Sox10 in spinal cord from mice with indicated genotypes at E12.5 and E14.5. e The quantification of the number of OPCs (Pdgfrα and Sox10 double positive) in spinal cord from mice with indicated genotypes at E12.5 and E14.5 (one-way ANOVA followed Tukey test, * P < 0.05, ** P < 0.01, *** P < 0.001, n = 6 per group). f Immunostainings of Pdgfrα/Olig2/BrdU in the cultured OPCs after incubation with BrdU (50 μg/ml) for 2 h. The bar graph ( g ) depicts the quantification of the percentage of BrdU + Pdgfrα + Olig2 + cells (one-way ANOVA followed Tukey test, * P < 0.05, n = 4 per group). h BrdU (50 mg/kg) was intraperitoneally injected into P6 mice. 2 h later, the mice were sacrificed and the brain sections of corpus callosum were immunostained with anti-Pdgfrα and anti-Ki67 (upper panel) or anti-BrdU (bottom panel) antibodies. Arrowheads indicate the proliferating OPCs (Pdgfrα and Ki67/BrdU double-positive cells). i The quantification of the number and percentage of proliferating OPCs from mice with indicated genotypes (one-way ANOVA followed Tukey test, * P < 0.05, *** P < 0.001, Pdgfrα + Ki67 + : n = 6 each group; Pdgfrα + BrdU + : n = 7 each group; Proliferation OPCs Pdgfrα + BrdU + /Pdgfrα + : n = 7 each group). j Immunostainings of O4/Olig2 and Mbp/Olig2 in oligodendrocytes after 3 days of T3 treatment. The bar graph ( k ) depicts the quantification of the percentage of O4 + Olig2 + and Mbp + Olig2 + cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). l Gene expressions of T3-induced differentiated oligodendrocytes from mice with indicated genotypes (one-way ANOVA followed Tukey test, *** P < 0.001, n = 4 per group)
Olig2 Cre Transgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/olig2-+cre+mice/olig2+cre+mice/pmc06318280-209-15-20
Average 90 stars, based on 1 article reviews
olig2-cre transgenic mice - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Prrc2a modulates oligodendroglia fate determination, proliferation, and differentiation in vitro. a Immunostainings of Pdgfrα/Olig2 or GFAP in oligosphere-derived cells 14 days postBl04-CM treatment from mice with indicated genotypes. b Quantification of the percentage of Pdgfrα + Olig2 + and GFAP + cells from mice with indicated genotypes (one-way ANOVA followed Tukey test, ** P < 0.01, n = 4 each group). c Gene expressions during neurosphere to oligosphere transformation in cells 14 days post B104-CM treatment. The gene expressions were normalized to those in wild-type neural stem cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). d Immunostainings of Pdgfrα and Sox10 in spinal cord from mice with indicated genotypes at E12.5 and E14.5. e The quantification of the number of OPCs (Pdgfrα and Sox10 double positive) in spinal cord from mice with indicated genotypes at E12.5 and E14.5 (one-way ANOVA followed Tukey test, * P < 0.05, ** P < 0.01, *** P < 0.001, n = 6 per group). f Immunostainings of Pdgfrα/Olig2/BrdU in the cultured OPCs after incubation with BrdU (50 μg/ml) for 2 h. The bar graph ( g ) depicts the quantification of the percentage of BrdU + Pdgfrα + Olig2 + cells (one-way ANOVA followed Tukey test, * P < 0.05, n = 4 per group). h BrdU (50 mg/kg) was intraperitoneally injected into P6 mice. 2 h later, the mice were sacrificed and the brain sections of corpus callosum were immunostained with anti-Pdgfrα and anti-Ki67 (upper panel) or anti-BrdU (bottom panel) antibodies. Arrowheads indicate the proliferating OPCs (Pdgfrα and Ki67/BrdU double-positive cells). i The quantification of the number and percentage of proliferating OPCs from mice with indicated genotypes (one-way ANOVA followed Tukey test, * P < 0.05, *** P < 0.001, Pdgfrα + Ki67 + : n = 6 each group; Pdgfrα + BrdU + : n = 7 each group; Proliferation OPCs Pdgfrα + BrdU + /Pdgfrα + : n = 7 each group). j Immunostainings of O4/Olig2 and Mbp/Olig2 in oligodendrocytes after 3 days of T3 treatment. The bar graph ( k ) depicts the quantification of the percentage of O4 + Olig2 + and Mbp + Olig2 + cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). l Gene expressions of T3-induced differentiated oligodendrocytes from mice with indicated genotypes (one-way ANOVA followed Tukey test, *** P < 0.001, n = 4 per group)

Journal: Cell Research

Article Title: A novel m 6 A reader Prrc2a controls oligodendroglial specification and myelination

doi: 10.1038/s41422-018-0113-8

Figure Lengend Snippet: Prrc2a modulates oligodendroglia fate determination, proliferation, and differentiation in vitro. a Immunostainings of Pdgfrα/Olig2 or GFAP in oligosphere-derived cells 14 days postBl04-CM treatment from mice with indicated genotypes. b Quantification of the percentage of Pdgfrα + Olig2 + and GFAP + cells from mice with indicated genotypes (one-way ANOVA followed Tukey test, ** P < 0.01, n = 4 each group). c Gene expressions during neurosphere to oligosphere transformation in cells 14 days post B104-CM treatment. The gene expressions were normalized to those in wild-type neural stem cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). d Immunostainings of Pdgfrα and Sox10 in spinal cord from mice with indicated genotypes at E12.5 and E14.5. e The quantification of the number of OPCs (Pdgfrα and Sox10 double positive) in spinal cord from mice with indicated genotypes at E12.5 and E14.5 (one-way ANOVA followed Tukey test, * P < 0.05, ** P < 0.01, *** P < 0.001, n = 6 per group). f Immunostainings of Pdgfrα/Olig2/BrdU in the cultured OPCs after incubation with BrdU (50 μg/ml) for 2 h. The bar graph ( g ) depicts the quantification of the percentage of BrdU + Pdgfrα + Olig2 + cells (one-way ANOVA followed Tukey test, * P < 0.05, n = 4 per group). h BrdU (50 mg/kg) was intraperitoneally injected into P6 mice. 2 h later, the mice were sacrificed and the brain sections of corpus callosum were immunostained with anti-Pdgfrα and anti-Ki67 (upper panel) or anti-BrdU (bottom panel) antibodies. Arrowheads indicate the proliferating OPCs (Pdgfrα and Ki67/BrdU double-positive cells). i The quantification of the number and percentage of proliferating OPCs from mice with indicated genotypes (one-way ANOVA followed Tukey test, * P < 0.05, *** P < 0.001, Pdgfrα + Ki67 + : n = 6 each group; Pdgfrα + BrdU + : n = 7 each group; Proliferation OPCs Pdgfrα + BrdU + /Pdgfrα + : n = 7 each group). j Immunostainings of O4/Olig2 and Mbp/Olig2 in oligodendrocytes after 3 days of T3 treatment. The bar graph ( k ) depicts the quantification of the percentage of O4 + Olig2 + and Mbp + Olig2 + cells (one-way ANOVA followed Tukey test, ** P < 0.01, *** P < 0.001, n = 4 per group). l Gene expressions of T3-induced differentiated oligodendrocytes from mice with indicated genotypes (one-way ANOVA followed Tukey test, *** P < 0.001, n = 4 per group)

Article Snippet: Similarly, specific deletion of Prrc2a in astrocytes was obtained through crossing Prrc2a f/f mice with Gfap - Cre transgenic mice (Jackson Laboratory, Stock Number: 024098, Cre recombinase was driven by the mouse glial fibrillary acidic protein promoter).

Techniques: In Vitro, Derivative Assay, Transformation Assay, Cell Culture, Incubation, Injection

Fto transgene triggers hypomyelination. a MeRIP-qPCR analysis of Olig2 RNA in m 6 A peak region in Fto transgenic (Tg) and wild-type (WT) mice at 4-weeks-old (two-tailed unpaired student’s t -test, *** P < 0.001, n = 4 per group). b Prrc2a RIP-qPCR analysis of Olig2 RNA in m 6 A peak region in Fto transgenic (Tg) and WT mice at 4 weeks old (two-tailed unpaired student’s t -test, ** P < 0.01, n = 4 per group). c Cultured OPCs from WT and Fto transgenic mice were exposed to actinomycin D (1 μg/ml), then RNA was isolated at indicated time points. RT-qPCR was performed to assess the half-lives of Olig2 mRNA. The data were presented as means ± s.e.m. and the inserted numbers ( T 1/2 (WT) = 73.3 ± 1.1 min; T 1/2(Tg) = 66.0 ± 0.6 min) show the calculated half-times from four independent experiments. d Volcano plot of RNA-seq data showing Fto-regulated genes from brain tissue samples of 4-week-old Fto transgenic vs. control mice. e Parts of GO terms of the biological process categories enriched in DEGs from Fto transgene vs. control samples. f Relative gene expression in hippocampus from 4-week-old Fto Tg and control mice (two-tailed unpaired student’s t -test, * P < 0.05, ** P < 0.01, *** P < 0.001, n = 4 per group). g Immunostainings of Pdgfrα (P7), CC1/Olig2, or Sox10 (P28) in corpus callosum from mice with indicated genotypes. The quantification of Pdgfrα + , CC1 + Olig2 + , and Sox10 + cells were shown in ( h ) (two-tailed unpaired student’s t -test, ** P < 0.01, *** P < 0.001, Pdgfrα + : n = 6 each group; CC1 + Olig2 + cells: n = 5 per group, Sox10 + cells: n = 5 per group). i T2-weighted MRI of 4-week-old mice with indicated genotypes. j Black-gold staining of brain sections from 4-, 8-, and 32-week-old Fto Tg and control mice. k The quantification of corpus callosum width at the midline from 4-, 8-, and 32-week-old Fto Tg and control mice (two-tailed unpaired student’s t -test, * P < 0.05, ** P < 0.01, 4w: n = 5 per group, 8w: n = 6 per group, 32w: n = 6 per group). l TEM analysis of the myelin fibers in the corpus callosum from mice with indicated genotypes and ages. The white arrowheads indicated the naked axons. m The percentage of myelinated axons in the corpus callosum from 4-, 8-, and 32-week-old mice with indicated genotypes (two-tailed unpaired student’s t -test, *** P < 0.001, 4w: n = 5 per group, 8w: n = 6 per group, 32w: n = 6 per group)

Journal: Cell Research

Article Title: A novel m 6 A reader Prrc2a controls oligodendroglial specification and myelination

doi: 10.1038/s41422-018-0113-8

Figure Lengend Snippet: Fto transgene triggers hypomyelination. a MeRIP-qPCR analysis of Olig2 RNA in m 6 A peak region in Fto transgenic (Tg) and wild-type (WT) mice at 4-weeks-old (two-tailed unpaired student’s t -test, *** P < 0.001, n = 4 per group). b Prrc2a RIP-qPCR analysis of Olig2 RNA in m 6 A peak region in Fto transgenic (Tg) and WT mice at 4 weeks old (two-tailed unpaired student’s t -test, ** P < 0.01, n = 4 per group). c Cultured OPCs from WT and Fto transgenic mice were exposed to actinomycin D (1 μg/ml), then RNA was isolated at indicated time points. RT-qPCR was performed to assess the half-lives of Olig2 mRNA. The data were presented as means ± s.e.m. and the inserted numbers ( T 1/2 (WT) = 73.3 ± 1.1 min; T 1/2(Tg) = 66.0 ± 0.6 min) show the calculated half-times from four independent experiments. d Volcano plot of RNA-seq data showing Fto-regulated genes from brain tissue samples of 4-week-old Fto transgenic vs. control mice. e Parts of GO terms of the biological process categories enriched in DEGs from Fto transgene vs. control samples. f Relative gene expression in hippocampus from 4-week-old Fto Tg and control mice (two-tailed unpaired student’s t -test, * P < 0.05, ** P < 0.01, *** P < 0.001, n = 4 per group). g Immunostainings of Pdgfrα (P7), CC1/Olig2, or Sox10 (P28) in corpus callosum from mice with indicated genotypes. The quantification of Pdgfrα + , CC1 + Olig2 + , and Sox10 + cells were shown in ( h ) (two-tailed unpaired student’s t -test, ** P < 0.01, *** P < 0.001, Pdgfrα + : n = 6 each group; CC1 + Olig2 + cells: n = 5 per group, Sox10 + cells: n = 5 per group). i T2-weighted MRI of 4-week-old mice with indicated genotypes. j Black-gold staining of brain sections from 4-, 8-, and 32-week-old Fto Tg and control mice. k The quantification of corpus callosum width at the midline from 4-, 8-, and 32-week-old Fto Tg and control mice (two-tailed unpaired student’s t -test, * P < 0.05, ** P < 0.01, 4w: n = 5 per group, 8w: n = 6 per group, 32w: n = 6 per group). l TEM analysis of the myelin fibers in the corpus callosum from mice with indicated genotypes and ages. The white arrowheads indicated the naked axons. m The percentage of myelinated axons in the corpus callosum from 4-, 8-, and 32-week-old mice with indicated genotypes (two-tailed unpaired student’s t -test, *** P < 0.001, 4w: n = 5 per group, 8w: n = 6 per group, 32w: n = 6 per group)

Article Snippet: Similarly, specific deletion of Prrc2a in astrocytes was obtained through crossing Prrc2a f/f mice with Gfap - Cre transgenic mice (Jackson Laboratory, Stock Number: 024098, Cre recombinase was driven by the mouse glial fibrillary acidic protein promoter).

Techniques: Transgenic Assay, Two Tailed Test, Cell Culture, Isolation, Quantitative RT-PCR, RNA Sequencing, Control, Gene Expression, Staining